Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Salvato, F. R.
  • Mason, Barbara

publication date

  • October 1994

journal

  • Alcoholism-Clinical and Experimental Research  Journal

abstract

  • A 38-year-old female was drinking 30 drinks/week before entering a 12-week, double-blind study of nalmefene for the treatment of alcohol dependence. Liver function tests (LFTs) were within normal limits at baseline and week 4, but on week 8, the ALT showed a 7-fold increase, and the AST showed a 4-fold increase from baseline. A decision was made to continue study medication based on the patient's positive response to this therapy (i.e., achieving complete abstinence) and no known dose-dependent association with liver toxicity in over 1300 patients treated with nalmefene for other indications. LFTs were repeated serially to assess the trend of the LFT values. The patient achieved total abstinence over the course of the study period and at the 3-month posttreatment follow-up was continuing to maintain these gains from the study program, and her LFTs had returned to normal. A gradual return to normal in ALT and AST, while treatment with nalmefene continued, does not support the role of nalmefene as an hepatotoxin. Relapse to drinking was excluded because of normal values for the gamma-glutamyltransferase, and verification of sobriety by self-report, significant other, and breathalyzer. A virology panel ruled out the presence of viral hepatitis. Dietary intake before the elevation in LFTs contained elements that have established association with hepatocellular changes. The routine prescription of serial LFTs in alcoholism pharmacotherapy trials may be expected to reveal clinically nonsignificant elevations that could potentially be related to exogenous factors, such as dietary composition and should not be reflexively attributed to medication under investigation and/or drinking.

subject areas

  • Adult
  • Alanine Transaminase
  • Alcoholism
  • Aspartate Aminotransferases
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Function Tests
  • Naltrexone
  • Narcotic Antagonists
scroll to property group menus

Research

keywords

  • ADVERSE DRUG REACTIONS
  • ALCOHOL DEPENDENCE
  • HEPATOTOXICITY
  • NALMEFENE
  • PHARMACOTHERAPY
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0145-6008

Digital Object Identifier (DOI)

  • 10.1111/j.1530-0277.1994.tb00102.x

PubMed ID

  • 7847604
scroll to property group menus

Additional Document Info

start page

  • 1187

end page

  • 1189

volume

  • 18

issue

  • 5

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support